Psoriasis is a chronic autoimmune skin disorder characterized by red, scaly patches that affect the skin, scalp, and joints. According to a study published in 2025, the global prevalence of psoriasis stands at 4.4%. It accounts for a significant portion of dermatological conditions, driving demand for better therapies. The growing focus on biologics, immunomodulators, and personalized treatments is shaping the future of psoriasis therapeutics. Recent advancements, including targeted biologic drugs, are expected to boost pipeline growth. The psoriasis pipeline analysis by the publisher highlights promising drug candidates under development, signaling strong potential for innovation in the coming years.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to psoriasis.
Psoriasis treatment includes topical agents, phototherapy, systemic medications, and biologic therapies. These medications target immune responses and reduce inflammation, helping to control flare-ups and improve the patient’s quality of life. For instance, Bimekizumab, an FDA-approved dual IL-17A/F inhibitor, emerged as a promising treatment for moderate to severe psoriasis by simultaneously targeting both key inflammatory cytokines, offering enhanced clinical efficacy.
Phosphodiesterase-4 (PDE4) inhibitors are gaining momentum in the psoriasis drug pipeline. For example, Arcutis Biotherapeutics’ investigational drug Zoryve (roflumilast) foam 0.3% targets scalp and body psoriasis in individuals aged 12 and older. Supported by strong Phase 2b and Phase 3 trial data, this once-daily topical therapy has shown significant efficacy, particularly in hard-to-treat scalp psoriasis, and is currently under review by the United States Food and Drug Administration.
LY3972406
LY3972406, sponsored by Eli Lilly and Company, is a part of a Phase II clinical trial to evaluate its efficacy and safety in adults with moderate-to-severe plaque psoriasis. The study investigates how LY3972406, an orally administered Kv1.3 inhibitor, works to modulate immune responses in autoimmune diseases, including psoriasis. The trial is currently enrolling an estimated 75 participants.
This product will be delivered within 3-5 business days.
Report Coverage
The Psoriasis Pipeline Analysis Report by the publisher gives comprehensive insights into psoriasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for psoriasis. The psoriasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The psoriasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with psoriasis treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to psoriasis.
Psoriasis Pipeline Outlook
Psoriasis is a chronic, immune-mediated skin disorder characterized by red, scaly plaques that typically appear on the elbows, knees, scalp, and lower back. It occurs due to an accelerated skin cell turnover triggered by immune system dysfunction, particularly involving T-cells and cytokines like interleukin-17 and interleukin-23. Genetic and environmental factors also contribute to its onset and severity.Psoriasis treatment includes topical agents, phototherapy, systemic medications, and biologic therapies. These medications target immune responses and reduce inflammation, helping to control flare-ups and improve the patient’s quality of life. For instance, Bimekizumab, an FDA-approved dual IL-17A/F inhibitor, emerged as a promising treatment for moderate to severe psoriasis by simultaneously targeting both key inflammatory cytokines, offering enhanced clinical efficacy.
Psoriasis Epidemiology
Recent epidemiological studies indicate a global psoriasis prevalence of 4.4%. Europe reports similar rates at 4.6%, while Asia shows a higher prevalence of 5.7%. In contrast, Latin America reports 3.1%, Africa 1.7%, and North America 3.7%. The Middle East records 4.9%. Urban areas have a higher prevalence of 4.8% compared to 3.8% in semi-urban and 4.3% in rural areas. Fair-skinned individuals show a slightly higher prevalence than dark-skinned individuals.Psoriasis - Pipeline Therapeutic Assessment
This section of the report covers the analysis of psoriasis drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Monoclonal Antibodies
- Topical Agents
- RNA-based therapies
- Natural Products & Botanical Extracts
- Others
By Route of Administration
- Oral
- Parenteral
- Others
Psoriasis Pipeline Assessment Segmentation by Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III holds the largest share in the psoriasis drug pipeline at 42.78%, reflecting strong advancements toward late-stage development. Phase IV accounts for 23.71%, while Phase II represents 19.07%. Phase I contributes 12.37%, and the early phase I covers 2.06%. This balanced pipeline highlights consistent innovation and promises a positive impact on future psoriasis treatment options and market growth.Psoriasis Pipeline Assessment Segmentation by Drug Classes
The drug molecule categories covered under the psoriasis pipeline analysis include small molecules, monoclonal antibodies, topical agents, RNA-based therapies, natural products & botanical extracts, and others. The psoriasis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for psoriasis.Phosphodiesterase-4 (PDE4) inhibitors are gaining momentum in the psoriasis drug pipeline. For example, Arcutis Biotherapeutics’ investigational drug Zoryve (roflumilast) foam 0.3% targets scalp and body psoriasis in individuals aged 12 and older. Supported by strong Phase 2b and Phase 3 trial data, this once-daily topical therapy has shown significant efficacy, particularly in hard-to-treat scalp psoriasis, and is currently under review by the United States Food and Drug Administration.
Psoriasis Clinical Trials - Key Players
The report for the psoriasis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed psoriasis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in psoriasis clinical trials:- Bausch Health Americas, Inc.
- Bristol-Myers Squibb
- Amgen
- Artax Biopharma Inc.
- SFA Therapeutics
- Innovent Biologics (Suzhou) Co. Ltd.
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Ganzhou Hemay Pharmaceutical Co., Ltd.
- BioRay Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- Hansoh BioMedical R&D Company
- Bio-Thera Solutions
Psoriasis - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for psoriasis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of psoriasis drug candidates.Drug: HS-10374
HS-10374, developed by Hansoh BioMedical R&D Company, is a novel, highly selective allosteric TYK2 inhibitor targeting IL-12 and IL-23 signaling, key cytokines in psoriasis. It is undergoing Phase III clinical development where it is being evaluated for its efficacy and safety in adults with moderate to severe plaque psoriasis. The trial is running over 52 weeks and aims to confirm its therapeutic potential and tolerability.LY3972406
LY3972406, sponsored by Eli Lilly and Company, is a part of a Phase II clinical trial to evaluate its efficacy and safety in adults with moderate-to-severe plaque psoriasis. The study investigates how LY3972406, an orally administered Kv1.3 inhibitor, works to modulate immune responses in autoimmune diseases, including psoriasis. The trial is currently enrolling an estimated 75 participants.
Drug: SFA002
SFA-002, backed by SFA Therapeutics, is currently undergoing a Phase I clinical study to evaluate its safety, metabolism, and efficacy in patients with mild to moderate chronic plaque psoriasis. This oral immunomodulator targets multiple inflammatory cytokines simultaneously. The study is enrolling 90 participants and is focusing on assessing both short-term and residual therapeutic effects.Reasons To Buy This Report
The Psoriasis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for psoriasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the psoriasis pipeline insights.Key Questions Answered in the Psoriasis Pipeline Insight Report
- Which companies/institutions are leading the psoriasis drug development?
- What is the efficacy and safety profile of psoriasis pipeline drugs?
- Which company is leading the psoriasis pipeline development activities?
- What is the current psoriasis commercial assessment?
- What are the opportunities and challenges present in the psoriasis pipeline landscape?
- What is the efficacy and safety profile of psoriasis pipeline drugs?
- Which company is conducting major trials for psoriasis drugs?
- Which companies/institutions are involved in psoriasis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in psoriasis?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Psoriasis
4 Patient Profile: Psoriasis
5 Psoriasis: Epidemiology Snapshot
6 Psoriasis: Market Dynamics
7 Psoriasis: Key Facts Covered
8 Psoriasis, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Psoriasis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Psoriasis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Psoriasis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Psoriasis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Psoriasis, Key Drug Pipeline Companies
